About
Inflarx N.v. (NASDAQ:IFRX) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 9 2026
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
Mar 31 2026
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
Mar 30 2026
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
Mar 19 2026
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
Mar 18 2026
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
Financials
Revenue
$29.33 K
Market Cap
$65.96 M
EPS
-0.79
Translate